European Patent Convention

Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent

Retrieved on: 
Thursday, January 4, 2024
SPA, Food, Reperfusion injury, PCI, STEMI, FDA, European, Patent, Ischemia, Death, European Patent Convention, Michael Faraday, Safety, EPO, Patient, Heart failure, Pharmaceutical industry

The company also announced its receipt of a notice of “intention to grant” its FDY-5301 patent application from the European Patent Office (EPO), allowing for the expansion of FDY-5301’s protection across the European Union (EU) into 2035.

Key Points: 
  • The company also announced its receipt of a notice of “intention to grant” its FDY-5301 patent application from the European Patent Office (EPO), allowing for the expansion of FDY-5301’s protection across the European Union (EU) into 2035.
  • The SPA amendment optimizes the timing, based on the study’s current enrollment rate, and expands the data set of the interim analysis.
  • The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration.
  • For more information on the IOCYTE AMI-3 Phase 3 please visit ClinicalTrials.gov and reference Identifier NCT04837001 .

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

Retrieved on: 
Thursday, January 4, 2024
Treatment, Bacteria, Therapy, Patent, Viral, Infection, European Patent Convention, EPO, Vaccine

The patent, titled “Methods of Treatment of Infections Using Bacteria,” (Application 19 866 580.4) provides protections for the application of the Company’s Decoy technology platform alone or in combination with standards of care for the prevention or treatment of any viral infection.

Key Points: 
  • The patent, titled “Methods of Treatment of Infections Using Bacteria,” (Application 19 866 580.4) provides protections for the application of the Company’s Decoy technology platform alone or in combination with standards of care for the prevention or treatment of any viral infection.
  • The EPO patent will be the second patent granted to Indaptus outside the United States for this application.
  • Jeffrey Meckler, Indaptus Therapeutics CEO, commented, “The continued protection of our intellectual property both in the U.S. and abroad will provide a competitive advantage for the Company, which should ultimately drive significant shareholder value over time.
  • We continue to explore the applications of our technology platform beyond solid tumors, for which we are currently engaged in a Phase 1 clinical trial, and look forward to updating our shareholders on scientific progress.”

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Retrieved on: 
Thursday, January 4, 2024
Doctor of Pharmacy, Conference, Family, SF3B1, PCT, Spacecraft, Patent, PH-1, MBA, Cancer, OTCQB, Interim, European Patent Convention, Patient, Therapy, ADC, PH1, Pharmaceutical industry

Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No.

Key Points: 
  • Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No.
  • The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it.
  • The patent granted by the USPTO covers claims for the Company’s potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1.
  • This patent application is a divisional patent of the Company’s R&D toxin portfolio on Thailanstatin, termed PH-1, building on the portfolio of previously issued patents (Patent No.

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Retrieved on: 
Wednesday, January 3, 2024
Invention, MRI, Physician, Software, Helix, BDP, Heart, Patent, Knowledge, Letter, European Patent Convention, Patient, Data collection, Therapy, Heart failure, Pharmaceutical industry

Today, I am writing to share a brief update on our business development activities related to our Biotherapeutic Delivery Partnering (BDP) business and our Morph Access Innovations (Morph) business.

Key Points: 
  • Today, I am writing to share a brief update on our business development activities related to our Biotherapeutic Delivery Partnering (BDP) business and our Morph Access Innovations (Morph) business.
  • Our BDP efforts are enhanced by the experience of almost 500 patients treated with the Helix transendocardial biotherapeutic delivery systems in twelve clinical trials.
  • Morph products are used in each of our biotherapeutic delivery procedures, and have been used in thousands of vascular procedures over the years.
  • There are also recently published patent applications on both our Helix biotherapeutic delivery systems and our Morph steerable access technology that we continue to advance.

EQS-News: Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent

Retrieved on: 
Saturday, December 30, 2023
Partnership, News, Patent, DKSH, Infection, SARS-CoV-2, European Patent Convention, Pharmaceutical industry

DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally.

Key Points: 
  • DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally.
  • Moreover, Marinomed was also able to successfully establish the production of Carragelose lozenges with its new Turkish manufacturing partner Meksmar.
  • Marinomed already supplied first customers with products and plans to further expand the distribution of Carragelose lozenges in the future.
  • Ending the year with a new partnership, a European patent and a successful manufacturing process shows once more that Carragelose is a success story,” Andreas Grassauer, CEO of Marinomed, says.

Positive opinion from ISA-Israel patent office Provides the ability to file a patent application under the Patent Prosecution Highway (PPH) in the US

Retrieved on: 
Monday, December 18, 2023
Invention, Partner, PPH, PCT, Patent, BYND, BCAN, IP, European Patent Convention, EPO, 3D printing

A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.

Key Points: 
  • A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.
  • The Company also announced filing in 11 additional jurisdictions, including the European Patent Office (EPO), which includes 38 European countries.
  • The Company has strategically pursued accelerated processing through the Patent Prosecution Highway (PPH) for one of its inventions, aligning with international efforts to promote work-sharing among patent offices.
  • The Company is actively collaborating with legal experts, including Reinhold Cohn and Partners, to navigate the complex landscape of patent prosecution and ensure optimal outcomes.

RecycLiCo Battery Materials Secures Key European Patent for Lithium-ion Battery Recycling 

Retrieved on: 
Thursday, December 14, 2023
Recycling, Patent, CIC, OTCQB, European Patent Convention, Investment, EPO, ID4, Communication, Electric battery

SURREY, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”), TSX.V: AMY, OTCQB: AMYZF, FSE: ID4, a pioneer in sustainable lithium-ion battery recycling technology, is pleased to announce that the European Patent Office (EPO) has issued an official communication indicating its intention to grant the Company's first of two patent applications (Patent Application No.

Key Points: 
  • SURREY, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”), TSX.V: AMY, OTCQB: AMYZF, FSE: ID4, a pioneer in sustainable lithium-ion battery recycling technology, is pleased to announce that the European Patent Office (EPO) has issued an official communication indicating its intention to grant the Company's first of two patent applications (Patent Application No.
  • With patents already issued in the United States, South Korea, Japan, China, India, Australia, and Canada, the anticipated European patent will be the 14th issued patent for RecycLiCo internationally.
  • The recognition of RecycLiCo's novel technology in Europe is particularly noteworthy given the continent's aggressive push towards electrification and substantial investments in battery materials, battery production, electric vehicles, and battery recycling.
  • This latest development is a testament to the novelty of RecycLiCo's lithium-ion battery recycling process.

Beam Global Granted European Patent for Curbside Electric Vehicle Charging Infrastructure Products

Retrieved on: 
Tuesday, November 21, 2023
Partnership, Beam, Wind, Acquisition, RMI, City, Research, LED, Electricity, Jeff Bezos, SAN, Patent, Internet of things, Beam Suntory, Light, IP, Engineering, Growth, European Patent Convention, Transport, Carbon, Lighting, RMI (energy organization), EV, Renewable energy

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, has been granted another new patent by the European Patent Office that covers EV Standard™, the Company’s renewably energized streetlight replacement products which provide curbside EV charging.

Key Points: 
  • SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM , BEEMW), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, has been granted another new patent by the European Patent Office that covers EV Standard™, the Company’s renewably energized streetlight replacement products which provide curbside EV charging.
  • The European Patent Office granted European Patent No.
  • The patent was issued on July 12, 2023 in the European Patent Bulletin 2031 10.22.
  • The products will fill a significant gap in the current EV charging infrastructure market as electric vehicles become more widespread and the demand for on-street charging becomes urgent.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Diabetic neuropathy, LID, Pregabalin, Depression, Pain, Pain management, Gold, MD, Doctor of Philosophy, Chung, Gabapentin, Nerve, Patent, University, Anxiety, Neuropathic pain, CNS, Anesthesiology, Hyperalgesia, European Patent Convention, NMDAR, Central nervous system, Allodynia, EPO, Journal, Pharmacology, Levodopa-induced dyskinesia, Pharmaceutical industry

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Retrieved on: 
Tuesday, December 26, 2023
Brainstorm, Acquisition, Patent, Stem cell, Exosome, European Patent Convention, ALS, Therapy, Pharmaceutical industry

The European Patent office granted patent No.

Key Points: 
  • The European Patent office granted patent No.
  • 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suitable therapeutic for treating ALS.
  • The patent also grants claims for an isolated population of mesenchymal stem cells for use in treating ALS.
  • Securing this European patent, alongside our existing patents in the US, Canada, Israel, Brazil, and Japan, enhances our capability to forge new global commercial partnerships, further expanding the reach of NurOwn."